Thrombomodulin (TM) is a thrombin receptor on the endothelial cell surface that plays an important role in the regulation of the coagulation system (1). Recently, recombinant human soluble TM (TM-α) was developed as an anticoagulant for patients with disseminated intravascular coagulation (DIC). Recombinant human soluble TM represents a new class of anticoagulants and is composed of the active, extracellular domain of TM (2, 3). Like the endogenous TM, which is observed on the endothelial cells, TM-α binds to thrombin to inactivate coagulation, and the thrombin–TM-α complex activates protein C (2, 3). The activated protein C inactivates factors VIIIa and Va, consequently inhibiting thrombin generation (2, 3). In Europe and North America, clinical trials of recombinant human TM to treat septic patients with DIC are being conducted (4, 5). In Japan, TM-α has been used clinically for the treatment of DIC since May 2008 (3).
Acute renal dysfunction is a frequent complication in patients with DIC (6). Previous reports have indicated that TM-α is excreted mainly by the kidneys in healthy subjects (2, 3, 7). Although the metabolized form of TM-α with a low molecular weight is also excreted in urine, a large portion of the unchanged form of TM-α is excreted in the urine (3). Therefore, the dose of TM-α required in DIC patients with severe renal impairment was suggested to be decreased to one third of the normal dose. However, the pharmacokinetics and pharmacodynamics of TM-α in DIC patients with severe renal impairment have not yet been elucidated.
In the present study, we evaluated the pharmacokinetics and pharmacodynamics of TM-α in DIC patients with severe renal impairment. We also investigated the safety and efficacy of TM-α in these patients and then compared them with those without renal impairment.
PATIENTS AND METHODS
The present study was approved by the institutional review board of Hokkaido University Hospital. Written informed consent was obtained from patients or each patient’s family. The present study included patients who were administered TM-α (Ashahi Kasei Pharma Co, Tokyo, Japan) to treat DIC in the intensive care unit. Patients with chronic renal failure requiring hemodialysis were excluded. The diagnosis of DIC was based on the Japanese Association for Acute Medicine DIC diagnosis criteria (8). The severity of illness of the patients was evaluated according to the Acute Physiology and Chronic Health Evaluation (APACHE) II score at the time of administration of TM-α (9). Organ failure was assessed by the Sequential Organ Failure Assessment (SOFA) score at the administration of TM-α (10). Consciousness levels according to the APACHE II and SOFA scores were evaluated before sedation. The systemic inflammatory response syndrome score was assessed according to the American College of Chest Physicians/Society of Critical Care Medicine Consensus conference (11) at the time of administration of TM-α. The urine was collected for 24 h after the administration of TM-α. The creatinine clearance (CLcr) was measured based on the serum and urine creatinine levels and the urine volume for 24 h. Severe renal impairment was defined as CLcr of less than 30 mL/min according to the Food and Drug Administration Guidance for Industry (12). The patients were divided into two groups, those with and without severe renal impairment.
In all patients, a dose of 380 U/kg of TM-α was administered during a 30-min intravenous infusion. Blood samples were taken before the start of the first TM-α administration, and at 0.5, 2, 4, 8, and 24 h after the start of the administration. All samples were diluted (9:1 vol/vol) with 3.8% sodium citrate. The blood samples were promptly centrifuged, and plasma was separated. The samples were frozen at −80°C until analysis. Thereafter, a second dose of TM-α adjusted to one third of the first dose was administered to the patients with severe renal impairment, according to the current treatment protocol.
The plasma TM-α and soluble TM concentrations were measured by enzyme-linked immunosorbent assay using two types of mouse monoclonal antibodies against TM-α (13). Enzyme-linked immunosorbent assay is able to measure the unchanged form of TM-α, because the results of enzyme-linked immunosorbent assay correlated with those of a functional assay (14). Tissue factor–induced prothrombinase activity was measured by a slightly modified version of the method described in a previous report (7). Citrated plasma (200 μL) from the patients was incubated with 10 μL of 200 U/mL batroxobin (Pentapharm, Tokyo, Japan) for 10 min. After centrifugation, defibrinated plasma (20 μL) was incubated with 5 μL of a buffer solution containing 12,500 times diluted rabbit brain tissue factor, 0.1 mg/mL of phospholipid vesicles, and 60 mmol CaCl2. After a 10-min incubation, 5 μL of a buffer solution with or without 15 μmol/L prothrombin was added to the reaction mixture. After a 3-min incubation, 500 μL of 1 mmol/L S-2366 chromogenic substrate was added, and after another 1-min incubation, glacial acetic acid (50 μL) was added, and the absorbance was monitored at 405 nm. The prothrombinase activity (amount of thrombin formation) was calculated as the amount of thrombin (measured in μM) generated in 1 min after adding prothrombin minus that after adding the buffer.
The pharmacokinetic parameters of TM-α were analyzed by model-independent methods (noncompartment model) using the Phoenix WinNonlin (version 6.1; Pharsight, Mountain View, Calif) software package. Regarding the simulation curves after multiple dosing of 380 U/kg of TM-α to patients with and without severe renal impairment, the mean plasma concentrations in each group were analyzed by a two-compartment model, and the simulation curves were generated with these pharmacokinetic parameters using the previously mentioned software package.
All measurements are expressed as the mean (SD). The SPSS 15.0J statistical software package (SPSS Inc, Chicago, Ill) was used for all statistical analyses. Comparisons between the two groups were made using either Student t test or the χ2 test. P < 0.05 was considered to be statistically significant.
Twenty-one DIC patients who were treated with TM-α were included in this study. Eleven patients with a CLcr of less than 30 mL/min were classified into the severe renal impairment group. There were 10 patients without severe renal impairment included for comparison. Table 1 presents the characteristics of the patients. The renal SOFA scores of the patients with severe renal impairment were higher than those of the patients without severe renal impairment. The soluble TM shed from the endothelial cell surface before the administration of TM-α in the DIC patients with severe renal impairment was higher than in the DIC patients without severe renal impairment. Seven patients with severe renal impairment were treated with continuous renal replacement therapy (CRRT) during the study period. The CRRT circuit was set up using a cellulose triacetate hollow fiber 1.1 m2 hemofilter (UT-110, Nipro, Japan). In the seven investigated patients, the ultrafiltrate flow was defined as 1.0 L/h, and dialysate flow was infused in a countercurrent at rates of 1.0 L/h. Nafamostat mesylate was used as an anticoagulant for CRRT in all patients.
The plasma concentration of TM-α and prothrombinase activity in DIC patients with and without severe renal impairment are presented in Table 2. After the administration of TM-α, the prothrombinase activities in both groups were sufficiently inhibited during the observation period. No bleeding-related or other adverse events were observed. The mortality rates 28 days after the TM-α administration were 45% (5/11) and 20% (2/10) in the DIC patients with and without severe renal dysfunction, respectively.
The pharmacokinetic parameters of TM-α in the DIC patients are presented in Table 3. In the patients with severe renal impairment, the elimination half-life (T½) was prolonged to about 1.2 times that of the patients without severe renal impairment. In contrast, the maximum concentration (Cmax) in the patients with severe renal impairment was decreased compared with that in the patients without severe renal impairment, because volume of distribution at steady state (Vdss) was increased in the patients with severe renal impairment. However, none of these changes were statistically significant. In the severe renal impairment group, the pharmacokinetic parameters of TM-α in the patients with and without CRRT are presented in Table 4. There was no substantial difference between the patients with and without CRRT.
Based on the pharmacokinetic data, plasma time-concentration curves of TM-α in patients with and without severe renal impairment were simulated in two-compartment models (Fig. 1). When the same dose of TM-α (380 U/kg) was repeatedly administered every 24 h in the simulation, the trough levels of TM-α gradually increased, reaching 600 ng/mL at 120 h after the first administration.
The present study is the first report of the pharmacokinetics and pharmacodynamics of TM-α in DIC patients with severe renal impairment. The pharmacokinetics and pharmacodynamics of TM-α in DIC patients with severe renal impairment were only slightly different from those in DIC patients without severe renal impairment. However, the trough levels of TM-α increased gradually in the patients with severe renal impairment when the same dose (380 U/kg) of TM-α was repeatedly administered in the pharmacokinetic simulation.
Most of the plasma TM-α is excreted by the kidneys (2, 3, 7). In the healthy volunteers, 40% of the administered dose of TM-α was excreted during the first 24 h after the administration of TM-α (2, 7). Furthermore, Tsuruta et al. (3) indicated that TM-α was excreted in either an unchanged form (40%) or in a metabolized form (55%) in the urine during the first 24 h in an animal study using a rat model without DIC. However, in a rat model with severe renal impairment, the clearance of TM-α was not markedly decreased (3). The clearance of TM-α in the non-DIC rat with severe renal impairment was 80% of that in the normal rat (3). Our present study revealed similar results. We showed that the clearance of TM-α in the DIC patients with severe renal impairment was 80% of that in the DIC patients without severe renal impairment.
In the DIC patients with severe renal impairment, the decomposition of TM-α may increase, although the elimination of TM-α decreases.
Previous reports have indicated that albumin (15, 16) and antithrombin (17) leak from the capillary vessels into the interstitial space in critically ill patients, because of the increased vascular permeability. The vascular permeability increases in accordance with the increase in disease severity of the patients (15, 16). The molecular weight of TM-α (62,000 Da) (18) is almost the same as that of albumin (56,000 Da) and antithrombin (63,000 Da) (15–17). In the present study, the severity of the patients with severe renal impairment was higher than that in patients without severe renal impairment. In the patients with severe renal impairment, the Vdss of TM-α was larger than that in the patients without severe renal impairment, although the difference was not statistically significant because of the small study population. Therefore, the severity of this condition in patients may affect the Vdss and Cmax of TM-α because of the increased vascular permeability.
Seven patients with severe renal impairment were treated with CRRT during the administration of TM-α. The pharmacokinetics of the drugs with a small molecular weight are affected by CRRT because of the additional elimination enforced by the CRRT. The large molecular weight of TM-α (62,000), which is larger than that of albumin (56,000), suggests that the pharmacokinetics of TM-α are not likely to be affected by CRRT. In the present study, the clearance of TM-α was not significantly different between the patients with and without CRRT, although the number of patients examined was very small. A part of the administered TM-α has been reported to be metabolized to a low molecular fraction (3). The low molecular fraction of TM-α may be eliminated by CRRT, although its molecular weight is still unclear. However, the pharmacokinetics and pharmacodynamics of TM-α are not related to the elimination of TM-α fragments with a low molecular weight, which does not have any activity.
A phase III study of TM-α in Japan showed that the bleeding-related adverse events of TM-α were markedly lower than those related to heparin in DIC patients (19). Mohri et al. (20) indicated that the concentration of TM-α required for the direct inhibition of thrombin activity was 50 times higher than that for the inhibition of thrombin generation. Therefore, the plasma concentration of TM-α does not reach the level to directly inhibit thrombin activity in the clinical setting (19, 20). No adverse events were observed in the present study. In the pharmacokinetic simulation when the same dose of TM-α (380 U/kg) was repeatedly administered to the two groups, the trough levels of TM-α increased gradually in the patients with severe renal impairment (Figure 1). Although the simulated concentrations of TM-α in the patients with severe renal impairment did not reach levels high enough to directly inhibit thrombin activity, the potential effect of this elevation in the trough levels on bleeding-related adverse effects is unclear. Confirmation of the actual pharmacokinetics and safety of repeated administration of the normal dose of TM-α in DIC patients with severe renal impairment will be needed.
Thrombomodulin is an endothelial cell membrane protein that plays an important role in the protein C system (1). In critically ill patients, soluble TM fragments circulate in the plasma as a result of endothelial cell activation and damage (21). The concentrations of soluble TM were reported to be around 10 ng/mL in critically ill patients (21). In the present study, the soluble TM originating from the endothelial cells before the administration of TM-α in the DIC patients with severe renal impairment was higher than that in the DIC patients without severe renal impairment. However, the concentrations of soluble TM were less than 15 ng/mL in the present study, the same as in the previous studies (21). The measured values of TM-α used for this pharmacokinetic/pharmacodynamic study included the soluble TM shed from the endothelial cells. However, the influence of this soluble TM on the measurement of the entire TM-α concentration is minimal, because the soluble TM level is much lower (<15 ng/mL) than the TM-α concentration that is observed for therapeutic administration (>300 ng/mL).
The present study has the same limitations, because the effects of the first administration were investigated, and there were simulated plasma time-concentration curves for TM-α. Furthermore, the number of patients evaluated in the present study was relatively small. Therefore, further large-scale clinical studies will be needed to clarify the appropriate adjustment of TM-α administration based on the patient renal function.
In conclusion, we herein clarified the pharmacokinetics and pharmacodynamics of TM-α in DIC patients with severe renal impairment. The clearance of TM-α in the patients with severe renal impairment was similar to that in the patients without severe renal impairment. However, a pharmacokinetic simulation of multiple administrations demonstrated an elevation of the trough levels of TM-α.
1. Esmon CT: The interactions between inflammation and coagulation. Br J Haematol 131 (4): 417–430, 2005.
2. Nakashima M, Kanamaru M, Umemura K, Tsuruta K: Pharmacokinetics and safety of a novel recombinant soluble human thrombomodulin, ART-123, in healthy male volunteers. J Clin Pharmacol 38 (1): 40–44, 1998.
3. Tsuruta K, Kodama T, Serada M, Hori K, Inaba A, Miyake T, Kohira T: Pharmacokinetics of recombinant human soluble thrombomodulin, thrombomodulin alfa in the rat. Xenobiotica 39 (2): 125–134, 2009.
4. van Iersel T, Stroissnig H, Giesen P, Wemer J, Wilhelm-Ogunbiyi K: Phase I study of solulin, a novel recombinant soluble human thrombomodulin analogue. Thromb Haemost 105 (2): 302–312, 2011.
5. Safety and efficacy of ART-123 in subjects with sepsis and disseminated intravascular coagulation. Available at: http://clinicaltrials.gov/ct2/show/NCT00487656
. Accessed April 4, 2012.
6. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP: The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 273 (2): 117–123, 1995.
7. Nakashima M, Uematsu T, Umemura K, Maruyama I, Tsuruta K: A novel recombinant soluble human thrombomodulin, ART-123, activates the protein C pathway in healthy male volunteers. J Clin Pharmacol 38 (6): 540–544, 1998.
8. Gando S, Saitoh D, Ogura H, Mayumi T, Koseki K, Ikeda T, Ishikura H, Iba T, Ueyama M, Eguchi Y, et al.: Natural history of disseminated intravascular coagulation diagnosed based on the newly established diagnostic criteria for critically ill patients: results of a multicenter, prospective survey. Crit Care Med 36 (1): 145–150, 2008.
9. Knaus WA, Draper EA, Wagner DP, Zimmerman JE: APACHE II: a severity of disease classification system. Crit Care Med 13 (10): 818–829, 1985.
10. Vincent JL, de Mendonca A, Cantraine F, Moreno R, Takala J, Suter PM, Sprung CL, Colardyn F, Blecher S: Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on “sepsis-related problems” of the uropean Society of Intensive Care Medicine. Crit Care Med 26 (11): 1793–1800, 1998.
11. The ACCP/SCCM Consensus Conference Committee: American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20 (6): 864–874, 1992.
12. US Department of Health and Human Services Food and Drug Administration: Pharmacokinetics in patients with impaired renal function. Study design, data analysis, and impact on dosing and labeling. Guidance for Industry 1998. Available at: http://http://www.fda.gov
/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072127.pdf. Accessed April 4, 2012.
13. Tsuruta K, Yamada Y, Serada M, Tanigawara Y: Model-based analysis of covariate effects on population pharmacokinetics of thrombomodulin alfa in disseminated intravascular coagulation (DIC) patients and normal subjects. J Clin Pharmacol 51 (9): 1276–1285, 2010.
14. Moll S, Lindley C, Pescatore S, Morrison D, Tsuruta K, Mohri M, Serada M, Sata M, Shimizu H, Yamada K, et al.: Phase I study of a novel recombinant human soluble thrombomodulin, ART-123. J Thromb Haemost 2 (10): 1745–1751, 2004.
15. Margarson MP, Soni N: Serum albumin: touchstone or totem? Anaesthesia 53 (8): 789–803, 1998.
16. Aman J, van der Heijden M, van Lingen A, Girbes AR, van Nieuw Amerongen GP, van Hinsbergh VW, Groeneveld AB: Plasma protein levels are markers of pulmonary vascular permeability and degree of lung injury in critically ill patients with or at risk for acute lung injury/acute respiratory distress syndrome. Crit Care Med 39 (1): 89–97, 2011.
17. Aibiki M, Fukuoka N, Umakoshi K, Ohtsubo S, Kikuchi S: Serum albumin levels anticipate antithrombin III activities before and after antithrombin III agent in critical patients with disseminated intravascular coagulation. Shock 27 (2): 139–144, 2007.
18. Mohri M: ART-123: recombinant human soluble thrombomodulin. Cardiovascular Drug Reviews 18 (4): 312–325, 2000.
19. Saito H, Maruyama I, Shimazaki S, Yamamoto Y, Aikawa N, Ohno R, Hirayama A, Matsuda T, Asakura H, Nakashima M, et al.: Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 5 (1): 31–41, 2007.
20. Mohri M, Sugimoto E, Sata M, Asano T: The inhibitory effect of recombinant human soluble thrombomodulin on initiation and extension of coagulation–a comparison with other anticoagulants. Thromb Haemost 82 (6): 1687–1693, 1999.
21. Reinhart K, Bayer O, Brunkhorst F, Meisner M: Markers of endothelial damage in organ dysfunction and sepsis. Crit Care Med 30 (5 Suppl): S302–S312, 2002.